Ophthalmology sits at the intersection of biosimilar disruption, gene therapy innovation, and a persistent patient and physician push to reduce treatment burden, particularly the frequency of intravitreal injections that define the current standard of care in retinal disease. For brand teams navigating this environment, the questions that matter most are not answered by claims data. They are answered by understanding how retinal specialists are thinking about biosimilar adoption, what is driving therapy selection in AMD and DME, and where gene therapy fits into a prescribing calculus that did not exist five years ago.

Spherix works with leading pharmaceutical manufacturers and emerging biopharma companies across the full ophthalmology lifecycle, from pre-clinical pipeline validation through established commercial brand management. The Spherix ophthalmology team brings more than two decades of combined experience, with research presented at major ophthalmology conferences and cited in corporate presentations by leading manufacturers. The Spherix ophthalmology community is a maintained group of practicing ophthalmologists and retinal specialists, screened for active patient management across AMD, DME, GA, and the emerging gene-therapy landscape.